Stock Information
Halozyme Therapeutics, Inc. (HALO)
Ticker Symbol: HALO
Exchange: NASDAQ
Sector: Biotechnology
Market Cap: $11,380.44 mil
Piotroski score: 7
PE Ratio: 25.65
EPS (TTM): 3.35
Revenue (TTM): $13.73 M
Dividend Yield: N/A
ROE: 180.63%
Latest News
-
Merck Sinks 9.5% in a Week as It Scraps a Blood Cancer Drug and Healthcare Sells Off. Time to Buy?
Sat, Nov 21, 2026 10:15 AM
-
Halozyme Therapeutics: Paying Today For A Next Wave Nobody Can See Yet
Sat, Nov 21, 2026 8:03 AM
-
HALO Faces Legal Setback in Germany Over MRK's Keytruda SC, Stock Down
Fri, Nov 20, 2026 2:10 PM
-
JP Morgan Maintains Neutral on Halozyme Therapeutics, Raises Price Target to $81
Fri, Nov 20, 2026 1:35 PM
-
HC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $130 Price Target
Fri, Nov 20, 2026 7:32 AM
-
Sector Update: Healthcare Stocks Softer in Afternoon Trading
Thu, Nov 19, 2026 6:32 PM
-
HALO Stock Hits Over 3-Month Lows, As German Court Overturns Temporary Ban On Merck’s Keytruda SC
Thu, Nov 19, 2026 4:32 PM
-
Halozyme Provides Update on German Preliminary Injunction Hearing
Thu, Nov 19, 2026 2:20 PM
-
Halozyme Stock Slides, European Patent Fight With Merck Spurs Fresh Pressure
Thu, Nov 19, 2026 2:15 PM
-
Halozyme Therapeutics: 3 Technologies, Multiple Big Pharma Partnerships
Thu, Nov 19, 2026 1:23 PM
Key Financials
Financial data not available